TNFRSF17 and plasma cell myeloma: Chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA) produced unprecedented results in heavily pretreated relapsed and/or refractory multiple myeloma (MM).